<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Co-diagnostics Inc — News on 6ix</title>
<link>https://6ix.com/company/co-diagnostics-inc</link>
<description>Latest news and press releases for Co-diagnostics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/co-diagnostics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835580c78dffbe2df0ea70c.webp</url>
<title>Co-diagnostics Inc</title>
<link>https://6ix.com/company/co-diagnostics-inc</link>
</image>
<item>
<title>Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-invited-to-present-at-stop-tb-partnership-summit-in-washington-dc</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-invited-to-present-at-stop-tb-partnership-summit-in-washington-dc</guid>
<pubDate>Thu, 16 Apr 2026 13:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate in the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026. The Company will present the Co-Dx Mycobacterium tuberculosis ("MTB" or "TB") test on the Co-Dx PCR platform* during a roundtable discussion with U.S. government agencies and other U.S.-based private</description>
</item>
<item>
<title>Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-to-showcase-co-dx-pcr-platform-and-ce-ivd-solutions-at-escmid-2026-in-munich-germany</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-to-showcase-co-dx-pcr-platform-and-ce-ivd-solutions-at-escmid-2026-in-munich-germany</guid>
<pubDate>Tue, 14 Apr 2026 13:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will participate in the Congress of the European Society of Clinical Microbiology and Infectious Disease ("ESCMID Global") 2026, taking place April 17-21 in Munich, Germany.</description>
</item>
<item>
<title>Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-executives-to-participate-in-european-trade-mission-with-utah-governor-and-wtc-utah</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-executives-to-participate-in-european-trade-mission-with-utah-governor-and-wtc-utah</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Trade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS,</description>
</item>
<item>
<title>Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-joint-venture-comira-receives-approval-for-manufacturing-facility-in-kingdom-of-saudi-arabias-sudair-industrial-city</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-joint-venture-comira-receives-approval-for-manufacturing-facility-in-kingdom-of-saudi-arabias-sudair-industrial-city</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Facility in Sudair Industrial City is expected to position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions in Saudi</description>
</item>
<item>
<title>Co-Diagnostics Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-reports-full-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-reports-full-year-2025-financial-results-1</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Advancing Global Commercialization Strategy Through CoSara and CoMira Joint VenturesProgressing Clinical Pipeline and Regulatory Pathways for PCR</description>
</item>
<item>
<title>Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-ships-diagnostic-materials-to-india-for-initiation-of-tuberculosis-clinical-studies-following-recently-issued-guidance-from-the-world-health-organization</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-ships-diagnostic-materials-to-india-for-initiation-of-tuberculosis-clinical-studies-following-recently-issued-guidance-from-the-world-health-organization</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>The near-term commencement of clinical studies is expected to align with recent WHO tuberculosis recommendations for near-point-of-care molecular testing and</description>
</item>
<item>
<title>Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-signs-agreement-to-significantly-expand-commercial-and-distribution-territory-across-south-asia</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-signs-agreement-to-significantly-expand-commercial-and-distribution-territory-across-south-asia</guid>
<pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
<description>Expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro® and</description>
</item>
<item>
<title>Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-announces-fourth-quarter-and-full-year-2025-earnings-release-date-and-webcast</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-announces-fourth-quarter-and-full-year-2025-earnings-release-date-and-webcast</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>SALT LAKE CITY, March 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique,</description>
</item>
<item>
<title>Co-Diagnostics to Present at Medical Korea 2026</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-to-present-at-medical-korea-2026</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-to-present-at-medical-korea-2026</guid>
<pubDate>Mon, 16 Mar 2026 13:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Co-Dx will accompany World Trade Center (WTC) Utah, the Utah Governor's Office of Economic Opportunity (GOEO), BioUtah, and other legislative and industry leaders at Medical Korea 2026, taking place March 19-22 in Seoul, South Korea.</description>
</item>
<item>
<title>Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-receives-japanese-patent-covering-co-dx-pcr-platform-technologies-10</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-receives-japanese-patent-covering-co-dx-pcr-platform-technologies-10</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>SALT LAKE CITY, March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique,</description>
</item>
<item>
<title>Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-regains-compliance-with-nasdaq-listing-requirements</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-regains-compliance-with-nasdaq-listing-requirements</guid>
<pubDate>Tue, 10 Mar 2026 13:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 9, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price rule. As a result, the previously discl</description>
</item>
<item>
<title>Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-showcase-pcr-platform-140000614</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-showcase-pcr-platform-140000614</guid>
<pubDate>Mon, 09 Feb 2026 14:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in an exhibition at the upcoming World Health Expo Labs Dubai ("WHX Labs"), taking place February 10–13, 2026, at the Dubai World Trade Centre.</description>
</item>
<item>
<title>Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-joint-venture-cosara-140000205</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-joint-venture-cosara-140000205</guid>
<pubDate>Thu, 05 Feb 2026 14:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has received a license from the Central Drugs Standard Control Organization ("CDSCO") to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument for sale or dis</description>
</item>
<item>
<title>Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-jv-cosara-receives-140000666</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-jv-cosara-receives-140000666</guid>
<pubDate>Wed, 04 Feb 2026 14:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has successfully completed the necessary audits of its quality management system ("QMS") and that its manufacturing facility located in Vadodara, India, has been granted ISO 1</description>
</item>
<item>
<title>Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-jv-cosara-participates-140000089</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-jv-cosara-participates-140000089</guid>
<pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has been strengthening its distributor base across India, recently attending and participating in two regional conferences.</description>
</item>
<item>
<title>Co-Diagnostics Announces Reverse Stock Split</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-announces-reverse-stock-140000418</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-announces-reverse-stock-140000418</guid>
<pubDate>Tue, 30 Dec 2025 14:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-30 shares. The reverse stock split will become effective at 12:01 a.m. ET on Friday, January 2, 2026. Co-Dx's common stock will conti</description>
</item>
<item>
<title>Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-receives-grant-australian-140000850</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-receives-grant-australian-140000850</guid>
<pubDate>Mon, 29 Dec 2025 14:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, strengthening Co-Dx's intellectual property portfolio surrounding its novel Co-Dx PCR platform*.</description>
</item>
<item>
<title>Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-joint-venture-cosara-140000551</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-joint-venture-cosara-140000551</guid>
<pubDate>Thu, 18 Dec 2025 14:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture, CoSara Diagnostics Pvt. Ltd. ("CoSara"), has been invited to participate in the 2nd Advanced TB Diagnostics Course, a capacity-building workshop for countries in the South-East Asian Region (SEAR). The event will take place December 15-19, 2025 at the ICMR–National Institute for</description>
</item>
<item>
<title>Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-performs-analysis-influenza-140000098</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-performs-analysis-influenza-140000098</guid>
<pubDate>Wed, 17 Dec 2025 14:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming comparable reactivity of the primer sets against the influenza A</description>
</item>
<item>
<title>Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025</title>
<link>https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-present-co-dx-140000607</link>
<guid isPermaLink="true">https://6ix.com/company/co-diagnostics-inc/news/co-diagnostics-present-co-dx-140000607</guid>
<pubDate>Tue, 09 Dec 2025 14:00:00 GMT</pubDate>
<description>Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company is delivering a presentation at the Point-of-Care Testing 2025 Exhibition and Conference in Boston, MA.</description>
</item>
</channel>
</rss>